-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们将目标价从87美元下调至65美元，基于2027年每股收益预期5.51美元，市盈率为11.8倍，较该股18.1倍的平均预期市盈率大幅折让。我们将2026年调整后每股收益预期从4.96美元下调至4.86美元，处于下调后的预期区间4.80美元至5.00美元的下限（此前预期为4.95美元至5.15美元）。通用电气医疗集团（GEHC）第一季度有机收入同比增长2.9%，达到预期上限。然而，其盈利能力指标令人失望，调整后每股收益为0.99美元，低于预期，调整后息税前利润率同比下降150个基点。这主要是由于PDx业务中一家供应商出现问题以及通胀成本意外上涨所致。因此，GEHC下调了其利润和现金流预期，我们认为这是一个审慎的举措。从战略角度来看，我们认为GEHC正在推进强大的创新产品线，已完成对Intelerad的收购，并宣布将影像和AVS业务部门合并为一个新的业务部门，这有望加速其增长。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Cincinnati Financial Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price by $7 to $185, valuing CINF shares (currently yielding 2%) at 20x our 2027 operating EPS estimate of $9.15 (raised by $0.10) and at 21.5x our 2026 EPS estimate of $8.60 (raised by $0.10), versus its five-year average forward multiple of 21x and peer average. CINF posted Q1 operating EPS of $2.10 versus a $0.24 operating loss per share a year ago, matching our estimate and topping the $1.94 consensus view, amid 12% higher operating revenues due to 11% premium growth and 14% higher net investment income, with written premium growth of 7% likely at the upper end of peer averages. We believe CINF's competitive strengths include its facile underwriting style and ability to allocate underwriting capital to areas with the most promising fundamentals, positioning it well despite increasingly competitive market conditions. CINF's ability to consistently produce above-peer growth and underwriting profitability will support the shares' premium valuation versus peers, in our view.
$CINF
Research
Research Alert: CFRA Maintains Hold Opinion On Shares Of Linde Plc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $48 to $537, using a P/E of 27.1x, equal to LIN's average forward P/E over the last three years. We raise our 2026 EPS estimate by $0.05 to $18.03 and 2027 by $0.26 to $19.81. LIN reported Q1 adj. EPS of $4.33, beating consensus by $0.06, with 30% operating margins and 24% ROC demonstrating the resilience of its business model. Management raised the low end of full-year guidance to $17.60-$17.90 (7%-9% growth), citing confidence despite geopolitical headwinds. The $7.1B project backlog should reach $8B+ by year-end, driven by Electronics projects supporting AI chip manufacturing. Americas volumes grew 2% Y/Y with double-digit hardgoods growth, though EMEA remains challenged by weak industrial activity. Commercial space is emerging as a significant growth driver, with aerospace sales up double-digits. Helium supply tightness presents upside opportunity beyond guidance. We think shares are fully valued at 25.6x our 2027 EPS estimate, limiting upside potential in the near term.
$LIN
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Silgan Holdings Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $13 to $46, based on an EV/EBITDA of 8.9x our 2026 EBITDA estimate, in line with SLGN's three-year average multiple. We increase our 2026 EPS estimate by $0.05 to $3.90 and raise 2027's by $0.05 to $4.20. Metal containers started the year strong, up 2% Y/Y, with pet food product volume up 11%. Management continues to see a long runway for growth in the fragrance, beauty, and health care category now that it is fully integrated into the Weener portfolio. We anticipate further product launches and customer partnerships in 2027, driving growth in this space. Dispensing and specialty closures headwinds are due to higher-cost inventory with volumes adversely affected by severe weather events in North America. Management also noted that volume is likely to improve in 2H 2026 after securing new business wins that have yet to be commercialized but were secured earlier this year.
$SLGN